Skip to main content
. 2023 Mar 15;10(14):2206139. doi: 10.1002/advs.202206139

Figure 5.

Figure 5

miR‐224‐5p and miR‐361‐3p perform a preferable inhibitory effect on HPAECs dysfunction and mediate the protective role of SOX17‐associated exosomes in endothelial dysfunction. a) The schematic diagram for the conditional treatment of HPAECs. b) EdU assay for the influence of miR‐224‐5p and miR‐361‐3p overexpression on VEGF‐induced proliferation of HPAECs, **P < 0.01 versus miR negative control, #P < 0.05, ##P < 0.01, ###P < 0.001 versus VEGF + miR negative control, n = 6. c) Western blotting assay for the protein expression of caspase3 and cleaved‐caspase3 induced by serum‐free conditions in HPAECs treated with miR‐224‐5p and/or miR‐361‐3p mimics, **P < 0.01 versus miR negative control, #P < 0.05, ##P < 0.01, ###P < 0.001 versus Serum free + miR negative control, n = 3. d) Caspase‐3/7 assay kit was used to detect apoptosis induced by serum‐free culture in HPAECs treated with miR‐224‐5p and/or miR‐361‐3p mimics. e) Western blotting assay for the protein expression of nuclear NFκB p65 and p‐NFκB p65 stimulated by hypoxia in HPAECs treated with miR‐224‐5p and/or miR‐361‐3p mimics, ***P < 0.001 versus miR negative control, #P < 0.05, ##P < 0.01, ###P < 0.001 versus Hypoxia + miR negative control, n = 3–4. f) NFκB p65 transcription factor assay kits for the NFκB activity in HPAECs stimulated by hypoxia in HPAECs treated with miR‐224‐5p and/or miR‐361‐3p mimics, n = 6. g) Western blotting assay for the protein expression of nuclear NFκB p65 and p‐NFκB p65 induced by TNFα in HPAECs treated with miR‐224‐5p and/or miR‐361‐3p mimics, ***P < 0.001, ****P < 0.0001 versus miR negative control, #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 versus TNFα + miR negative control, n = 4. h) NFκB p65 transcription factor assay kits were used to measure the NFκB activity in HPAECs induced by TNFα in HPAECs treated with miR‐224‐5p and/or miR‐361‐3p mimics, n = 5–6.